Hologic (NASDAQ:HOLX) price target upped to $44.00, issued a ratings update earlier today by Barclays Capital
- Updated: September 23, 2016
Boasting a price of $38.78, Hologic (NASDAQ:HOLX) traded 0.46% higher on the day. With the last stock price close up 8.58% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Hologic has recorded a 50-day average of $38.36 and a two hundred day average of $35.88. Volume of trade was down over the average, with 199,993 shares of HOLX changing hands under the typical 2,433,530
Reporting as potential upside of 0.13%, Barclays Capital bumped up the target of Hologic (NASDAQ:HOLX) to $44.00
On 8/01/2016, RBC Capital Markets released a statement for Hologic (NASDAQ:HOLX) bumped up the target price from $37.00 to $39.00 that suggested a downside of 0.00%.
With a total market value of $0, Hologic has price-earnings ratio of 42.95 with a one year low of $31.84 and a one year high of $41.66 .
A total of 16 equity analysts have released a ratings update on HOLX. Eight equity analysts rating the company a strong buy, five equity analysts rating the company a buy, eight equity analysts rating the company a hold, zero equity analysts rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $42.25.
Brief Synopsis About Hologic (NASDAQ:HOLX)
Hologic, Inc. is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women's health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. Its Diagnostics products include its Aptima family of assays, which run on its advanced instrumentation systems (Panther and Tigris); ThinPrep system; the Rapid Fetal Fibronectin Test, and Procleix blood screening assays. Its Breast Health products include a portfolio of breast imaging and related products and accessories, including digital mammography systems, computer-aided detection for mammography and minimally invasive breast biopsy devices, breast biopsy site markers and breast biopsy guidance systems. Its GYN Surgical products include NovaSure Endometrial Ablation System and MyoSure Hysteroscopic Tissue Removal System. Its Skeletal Health segment offers Discovery and Horizon X-ray bone densitometers.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.